Fresenius SE & Co. KGaA (FRA:FRE) has been assigned a €74.50 ($86.63) target price by equities research analysts at Goldman Sachs Group, Inc. (The) in a note issued to investors on Tuesday. The brokerage currently has a “neutral” rating on the stock. Goldman Sachs Group, Inc. (The)’s price target points to a potential upside of 10.75% from the company’s previous close.

A number of other equities analysts have also recently issued reports on the company. Kepler Capital Markets set a €77.00 ($89.53) target price on Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a report on Wednesday, August 2nd. Citigroup Inc. set a €83.00 ($96.51) target price on Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a report on Thursday, October 19th. Warburg Research set a €78.00 ($90.70) target price on Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a report on Monday, October 30th. Bank of America Corporation set a €75.00 ($87.21) target price on Fresenius SE & Co. KGaA and gave the stock a “neutral” rating in a report on Monday, November 6th. Finally, Morgan Stanley set a €83.00 ($96.51) target price on Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a report on Wednesday, October 4th. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of €81.51 ($94.78).

Fresenius SE & Co. KGaA (FRA FRE) opened at €67.27 ($78.22) on Tuesday. Fresenius SE & Co. KGaA has a 1-year low of €65.00 ($75.58) and a 1-year high of €80.00 ($93.02).

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/14/goldman-sachs-group-inc-the-analysts-give-fresenius-se-74-50-price-target.html.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co. KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.